Hair‑Loss Pill Redefines Masculinity and Aging
The Hair-Loss Drug Rewriting the Rules of Masculinity A pill to cure baldness is changing the way men age — and how they see themselves. https://t.co/4OiLpmOwGR https://t.co/YQLBx61gVT
New Cytotoxic Targets Unveiled at AACR26
Time to head off the beaten track at #AACR26 with our latest preview exploring novel targets and cytotoxics. The long climb up the hill may be worth it for some of them: https://t.co/l9tkdWvpuF https://t.co/M5B3RTW1wf
Funding Hurdles Stall Needed Multi‑site BPC‑157 Trial
I can’t see any reason why a proper multi site RCT of BPC157 done by a few independent groups wouldn’t help clarify any real vs placebo effects. The challenge: no one wants to pony up the $ (more like $$$$...
Blueprint for Integrating Psilocybin Into NHS Mental Health Care
British Journal of Psychiatry Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin https://t.co/6sgfqg66rt
First Human Trial Tests Cellular Age Reversal Therapy
This method to reverse cellular ageing is about to be tested in humans A burgeoning field is launching its first clinical trial to find out whether dialling back cell development can safely refresh aged tissues and organs. 💡"Technologies to refresh ageing tissue...
Cash‑pay Market for $950 Humira Doubtful vs Cheap Biosimilars
Is there really a cash-pay market for a $950/month brand-name Humira? (...especially w/two adalimumab biosimilars priced at less than $300/mo. already on TrumpRx, and many insured folks paying $0-5/month) https://t.co/taeQUY6Rve
DTC Affiliate Marketing Shifts to GLP‑1s Amid Pharma Proxy War
Look, I'd be lying if I said this was the first (or second or fiftieth) MEDVi article. But this is about more than MEDVi or even all the spam, grey zone marketing, and Succession-level drama of business partners acquired by...
Gilead's $3.1B Deal Expands ADC Portfolio
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis https://t.co/xEMXvDq2LL by @gwendolynawu $GILD #biotech
Peptide Vials Contaminated, Underdosed, and Unsafe
Besides the lack of data for safety or efficacy on peptides, or any assurance of sterility, here's what an independent lab found of samples: —The vial of BPC-157 contained lead —The vial of TB-500 contained endotoxins —The vial of CJC-1295 contained <42% of...
Fund NIH Trials to Validate Unapproved Peptide Safety
I thought this was an excellent, balanced article on the current state of unapproved peptides from a safety and regulatory perspective by @AnjeanetteDamon in @propublica https://t.co/DbA8cdvTY5 The fundamental problem is that we don't have quality data on safety or efficacy for...
Oxytocin Reverses Isolation‑induced Neuropsychiatric Deficits via Brain, Immune, Microbiome
Oxytocin attenuates isolation-evoked emotional and social behavioral dysregulation through neural, immune, and microbiota mechanisms "Our study confirms the therapeutic effects of OXT in reversing isolation-induced neuropsychiatric disorders and elucidates its potential regulatory mechanisms, offering important implications for clinical interventions." https://t.co/hXkWRD1gMV
SNY's Atopic Dermatitis Candidate Fails; NKTR Rem
$SNY next-gen atopic dermatitis drug failed in P2b. Missed primary endpoint. MOA was IL13xTSLP. Now what have they got to follow up dupi if (when?) they discontinue amlitelimab? $NKTR 👀 🤷🏻♂️ Remains the only new MoA...
CEO Kazimi Explores Computation, Chemistry, Culture in Drug Discovery
Computation, Chemistry & Culture for Drug Discovery: Nimbus Therapeutics CEO Abbas Kazimi is the latest guest on The Long Run. Sponsored by @AlphaSenseInc and Dash Bio. https://t.co/XCysW6El1o
Tubulis Secures $5B Gilead Acquisition After CEO Vision
Last year I visited @Tubulis_GmbH in Munich, Germany. Here's what CEO Dominik Schumacher told me they were aiming to do. Congrats on today's acquisition by @gilead for up to $5B, and congrats to @schroederthilo who raved to me about this...
Four‑Month MDF Cuts NAFLD Liver Fat by 24%
"The 4-month intervention with this MDF was effective in reducing IHTC in patients with NAFLD by an absolute reduction of −5.89% and a relative reduction of −24.30% after adjusting for weight loss. Such effect was partly mediated by altered composition...
Real Progress Lies in 0‑to‑PCC Data, Not AI Hype
Check out my article in @FastCompany on AI drug discovery revolution. From one perspective, it may feel like I am turning into a version of Derek Lowe - AI skeptic. And when I read another interview with the IT...
Gene Therapy Poised to Redefine Obesity Treatment Landscape
1/GLP-1 obesity and weight-loss drugs - such as $NVO Ozempic & Wegovy and $LLY Zepbound & Mounjaro have long become a household name - making Obesity the fastest growing market in the BioTech and Pharma ecosystem and generating unprecedented revenues....
Digital Twins Simulate Psychedelic Effects for Consciousness Disorders
Digital twins allow virtual clinical trials of psychedelics for disorders of consciousness 🧠↔🧠 | Innovation | Tech for Good. 💬 Using magnetic resonance imaging (MRI), scientists have developed personalized, whole-brain computational models of patients with disorders of consciousness. Using these...
Neuronal NOS Inhibition Blocks mTOR, Halts Neuroblastoma Growth
Neuroblastoma cells rely on neuronal nitric oxide synthase to sustain mTOR signaling and proliferation; inhibiting this enzyme disrupts tumor growth in both cell culture and animal models, highlighting a promising upstream therapeutic target. cancerbiology
AI Meets Drug Discovery at NYC Meetup Tuesday
AI x Drug Discovery meetup next Tues (14) in NYC ! @ginkgo excited to host with @AAlphaBio — sign up here : https://t.co/GG5c7F4ogO
3D‑Printed Spanlastics Directly Target Tumors, Cut Side Effects
3D-printed spanlastics, microscopic carriers for cancer drugs, show potential to target tumors directly and reduce side effects by concentrating therapy at the tumor site rather than throughout the body. nanotechnology
One Psychedelic Dose Quickly Eases Depression, Trial Shows
Single dose of a psychedelic drug can rapidly reduce depressive symptoms, clinical trial suggests https://t.co/c72qpfwQPm https://t.co/xR7hbj4v8e
Repurposing Approved Drugs: Small Trials Explore New Uses
Great reporting from @Philanthropy on our grantee @CuresWReach, which runs small trials testing whether existing, approved drugs might work for entirely different diseases.
Egg Bioreactors Replace CHO Cells in Biologics Production
We’ve optimized drug design with AI. Why are we still manufacturing with CHO like it’s the 1980s? Neion Bio is rethinking biologics production using chicken eggs as bioreactors. Excited to hear Sam Levin at #SynBioBeta2026. Visit the SynBioBeta website to read the full...
Study Shows Subcutaneous Tepezza Matches Infused Version
Under-the-skin Tepezza comparable to infused version in key study, Amgen says https://t.co/rOQqbRmEpL $AMGN $VRDN - 25%
Immune Training Against Senescent Cells Reduces Tumor Growth
Here's my take on your paper: Cellular senescence or "zombie cell" events happen when a cell experiences too much genetic or epigenetic noise, caused by cellular damage (e.g. DNA breaks) or telomere erosion Your study of a Lewis Lung Carcinoma (LLC) mouse...
Diabetes Drug Replicates Exercise Effects in Prostate Cancer Patients
How a Diabetes Drug May Echo the Benefits of Exercise in Prostate Cancer Care “From a clinical standpoint, seeing a metabolic signal that mirrors what we associate with intense exercise was striking… For patients whose treatments or symptoms limit physical activity,...
Meta-Analyses Reveal Psychedelics Boost Brain Circuits
Two systematic, meta-analyses on psychedelic drugs today Brain Circuit Function @NatureMedicine https://t.co/nBmjreYEXU Depression @NatMentHealth https://t.co/zJR06AsC0Z https://t.co/qpWdjzBR4D
Eli Lilly's Oral GLP‑1 Faces Price War Threat
6April: Why are @EliLillyandCo investors concerned that sales of its just-approved oral GLP-1 may be dampened this year by a price war with @novonordisk? Read about $LLY & $NOVOB plus updates on $INO $ORIC & $SGMO in my latest StockWatch for @GENbio: https://t.co/leir6iyURg
Myeloma Survival Breakthrough: Two Decades After Dalton’s Wish
I remember interviewing Bill Dalton in 2005 about new developments in myeloma and how he wished for new regimens to take OS out beyond 3-4 yrs. Two decades on we've hit jackpot...
Promoting OSKM Therapy with MYC Is Borderline Criminal
The fact that some scientists are still touting OSKM as a therapy, which includes the cancer-causing oncogene MYC, is borderline criminal
FDA Backs Permanent Re‑authorization of Pediatric PRV Program
FDA calls to permanently re-authorize the rare pediatric disease PRV program in Friday's 2027 budget plan -- far cry from the FDA that complained to the GAO about PRVs as distracting from their public health priorities https://t.co/i79F7X1ECw
FDA Delay Shuts Down Small Biotech in Four Months
How a four-month FDA delay forced a small biotech company to close its doors https://t.co/6vMGJM5SjH
5-MeO-DMT Shows Remarkable Clinical Results and Unmeasured Benefits
The clinical data for 5-MeO-DMT in $ATAI ‘s treatment-resistant-depression trials is outstanding. Yet beyond the measurable endpoints, there’s indeed an additional layer of impact - difficult to capture in standard metrics, but consistently reported. @bryan_johnson captured this beautifully. And I...
Oncology Revenue Dominated by Few Classes, KRAS Next.
Great tables from Wedbush listing small molecule oncology and hemonc drugs ordered by approval date. I counted ~20 different classes for solid tumors and ~6 for liquid, most revenues are driven by a handful of classes that reached multi...
Low‑Cost Covid Vaccine Tech Delivers 100M Doses, Bypassing Big
So to clarify, Baylor Coll Med licensed our low-cost protein Covid vaccine technology to four entities: BioE (India), BioFarma (Indonesia), Incepta (Bangladesh), ImmunityBio (U.S./S. Africa). The first two produced and delivered 100 million vaccine doses as Corbevax for India and...
Psilocybin Single Dose Beats Nicotine Patches for Quitting
A single dose of psilocybin is more effective than nicotine patches for quitting smoking, study suggests https://t.co/APDQt1WYxp https://t.co/zDnXcUjFyG
Exercise‑linked Protein Target Could Rejuvenate Aging Blood‑brain Barrier
Scientists Find a Mechanism for How Exercise Protects the Brain 🗣️Finding drugs to trim proteins like TNAP could be a new way to rejuvenate the blood-brain barrier, even after it’s been degraded by age. “We’re uncovering biology that Alzheimer’s research has largely...
SIRT1 Activation Shows Promise for Age‑related Brain Disorders
SIRT1 Activators as Geroprotective Agents in Brain Aging: Mechanisms and Therapeutic Potential "...SIRT1 could be a promising pharmacological target for age-associated brain disorders, warranting more robust translational studies to validate these findings in humans..." https://t.co/hGVxZ4RErM
Cures Emerge From Incremental Advances, Not Single Breakthroughs
The media makes it seem like cures are one breakthrough away. In reality, cures come from smaller breakthroughs and improvements made by the work of thousands of scientists, drug developers and doctors. We’re witnessing this evolution in real time with...
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/fFVUqNssyX
Phase 3 Trial Tests Daratumumab
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/ClwxVAhSy0
Congress Must Reform Broken IND Process for FIH Trials
Great to see FDA & the administration prioritizing FIH (First in Human) reform. The current IND process is broken & has shifted FIH trials overseas. Countries like Australia have relied on a more flexible, notification-based pathway for years. Now Congress...
Levetiracetam Blocks Amyloid Beta via SV2a‑dependent APP Modulation
Levetiracetam prevents Aβ production through SV2a-dependent modulation of APP processing in Alzheimer’s disease models "...supporting the hypothesis that protein accumulation is a relevant pathogenic event in amyloid pathology..." https://t.co/bRqoZP1Qyf @ScienceTM
Machine Learning Links Spironolactone to Reduced Fibrosis Risk
Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma Proteomics https://t.co/Ho2RL0RhO4 https://t.co/cHkogagDTt
GLP‑1s Massively Marked up; LLMs Priced Near Cost
One observation here: GLP-1s are priced at maybe 25-50x production cost (not counting R&D). LLM usage is priced at perhaps 1x inference cost (not counting training). In any case, two great innovations that are rapidly catching on.
China Competition Will Accelerate US Pharma, Cut Red Tape
This is great to see. Biotech and pharma competition with China is going to force us to sharpen and accelerate processes in the US, and cut red tape. And we'll get the benefit of Chinese drugs as well. Win/win.
Intranasal EV Vaccine Shields Mice From H5N1, H7N9
A potential universal flu shot? Intranasal EV vaccine protected mice from H5N1, H7N9 https://t.co/WroXpi6YP3 https://t.co/umAPlnRjbF
Adrenal Organoid Replicates Human Development and Hormone Production
A new adrenal gland organoid accurately models human development and hormone production, offering a platform to study stress responses, disease mechanisms, and potential regenerative therapies for adrenal disorders. biotechnology
Silicon Valley's Immortality Bet Reaches 91‑year‑old
Longevity treatments for a 91-year-old. That's the kind of story that captures where Silicon Valley's immortality bet is actually heading. Great piece by @AmyDMarcus, who I had the chance to meet in Boston recently. She brings serious depth to this beat,...